about
Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegenerationLong-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.Axonal damage in multiple sclerosis plaques: a combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study.Low serum urate levels are associated to female gender in multiple sclerosis patients.Geographical variations in sex ratio trends over time in multiple sclerosis.Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificityInfluence of Interferon beta treatment on quality of life in multiple sclerosis patientsPatient expression of emotions and neurologist responses in first multiple sclerosis consultationsDevelopment of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection.The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.Prognostic indicators in pediatric clinically isolated syndrome.Assessing response to interferon-β in a multicenter dataset of patients with MS.Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies.Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy.Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort.Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis.Proton MR spectroscopy in idiopathic spasmodic torticollis.Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease.Life-threatening ADEM in an immunocompetent pregnant woman with concomitant asymptomatic Cytomegalovirus infection.Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis.Brain MRI correlates of magnetization transfer imaging metrics in patients with multiple sclerosis.A rare case of multiple sclerosis and McArdle disease.First mutation in the nuclear localization signal sequence of spastin protein identified in a patient with hereditary spastic paraplegia.Reversible splenial lesion and complex visual disturbances due to carbamazepine withdrawal.Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances.Natalizumab discontinuation and disease restart in pregnancy: a case series.Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatmentSerum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis opticaMS and related disorders: looking for markers of phenotypesCerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis
P50
Q21131975-EC4CFC39-736B-44C3-AC06-5C0D6442B46FQ31028236-30F976AC-7D1D-4804-8D84-99BF789E694CQ31800788-3BA94BE2-21A6-439A-96CA-D7174FA5C1A4Q34357957-974C5B62-58BA-4AFD-AF6E-78ED0F88E4A3Q34469310-41256EEA-C4CD-41DA-8E56-2A7D260CDF0BQ35048235-C3F80264-274F-46D8-B71E-F5F2A915836AQ35250764-D3522D44-A1B5-4A6D-A79F-7040E8586CC7Q35648386-28C2A782-CE16-4D44-AE57-B88DCA12100BQ35850484-ADA381F7-A298-4EAC-B78B-A231CD6803A5Q36070808-DE0C2D56-F65C-4A39-B988-F7C37E23CC1FQ38202636-00DF4AB7-36CC-43D0-B434-339C9B41A2BBQ38821503-F8D0E05A-160F-4005-AFBF-2DCE505A38F3Q39680742-38972F10-D082-4C6C-A1AD-B57FA2963B1EQ39692977-E13F7BED-0B56-479A-8851-86BF3BF82FC7Q39881740-8389A6BA-80DE-432E-A145-22DF996A13B2Q40071350-76906C0C-247D-42DB-898C-1725B7391394Q41027362-06128FDE-FC8A-4407-91F1-F8AA8583A98EQ41369754-4118BD18-8414-4F7F-A3AE-4B398FB921EBQ42262399-C7137CBF-B751-4702-8EFF-29121CE4448BQ42655958-A646BBBF-0DAC-44A3-98BB-DC363B0FDC9CQ43514569-30B83F3E-E518-4329-9793-F9607BA969C0Q43712417-D2DA16C3-0438-4BCE-BCCC-2D5B0AD39CC7Q47395782-B4250137-CE27-410E-9F5D-845DAB771461Q47440321-3E280523-245B-4BB6-8FA9-8FC4AE56BA41Q47958350-9F60A533-1AC9-4745-ACB3-B794A5D482FFQ48125322-433958A3-FE1C-46D0-B14E-C1F9F40AA5D6Q48170915-AE1494EA-5FC4-474F-91F3-8810016573F5Q48230478-DC4C4D2D-B052-48AE-B3F5-9C6C6C885D98Q48280517-470FDAB0-F067-42E6-A813-EAC9D8969A6AQ48740501-3B03B974-0D64-4449-AE4C-66DF846AB97DQ50764775-6CE30AF4-1C30-4BB2-9ED8-B78474C5AE62Q51063274-5775778A-BA96-41D3-BDB4-103F5E33D104Q51810980-ABAFB39D-EC9B-4053-9260-8BD00ED69D17Q52093939-53AB7C2C-8F23-47E8-A5BA-FC8A585CBC01Q52651142-2AA822C0-F811-49A2-BCC3-EC31E208D5BFQ52766222-E952E14A-C8BA-4B94-A04B-3B617DDE5E7FQ57911906-A685B9EF-02C5-48B1-8E9E-9C1BBCA1AFF8Q59389218-CB73F976-F17E-48E2-9642-E3DAFD8F47C7Q59649438-C586E990-35ED-4D35-AD02-064D51F8CF22Q59649439-8C219174-480B-413C-8357-9AAFE2520EFB
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carla Tortorella
@ast
Carla Tortorella
@en
Carla Tortorella
@es
Carla Tortorella
@nl
type
label
Carla Tortorella
@ast
Carla Tortorella
@en
Carla Tortorella
@es
Carla Tortorella
@nl
prefLabel
Carla Tortorella
@ast
Carla Tortorella
@en
Carla Tortorella
@es
Carla Tortorella
@nl
P106
P1153
7006355456
P21
P31
P496
0000-0001-9037-7300